(0.21%) 5 110.88 points
(0.34%) 38 368 points
(0.27%) 15 970 points
(-1.37%) $82.70
(5.77%) $2.03
(0.21%) $2 352.10
(0.01%) $27.54
(3.95%) $958.55
(-0.24%) $0.932
(-0.35%) $10.99
(-0.55%) $0.796
(1.65%) $93.39
-0.81% $ 4.91
Live Chart Being Loaded With Signals
Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders...
Stats | |
---|---|
Tagesvolumen | 1.06M |
Durchschnittsvolumen | 214 738 |
Marktkapitalisierung | 123.37M |
EPS | $0 ( 2024-03-12 ) |
Nächstes Ertragsdatum | ( $0 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.933 |
ATR14 | $0.143 (2.91%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-09-25 | Trask Anna | Sell | 106 864 | Common Stock |
2023-09-25 | Trask Anna | Sell | 45 000 | Stock Option (right to buy) |
2023-09-25 | Trask Anna | Sell | 52 500 | Stock Option (right to buy) |
2023-09-25 | Trask Anna | Sell | 137 302 | Stock Option (right to buy) |
2023-09-25 | Carson William H. | Sell | 5 000 | Common Stock |
INSIDER POWER |
---|
-72.47 |
Last 92 transactions |
Buy: 13 490 376 | Sell: 25 219 441 |
Volumen Korrelation
Decibel Therapeutics, Korrelation
10 Am meisten positiv korreliert | |
---|---|
BYFC | 0.916 |
BOOM | 0.915 |
MDXG | 0.906 |
ASLE | 0.893 |
CIGI | 0.893 |
SLMBP | 0.89 |
MBIN | 0.888 |
SNPO | 0.887 |
NEXT | 0.885 |
AIRS | 0.883 |
10 Am meisten negativ korreliert | |
---|---|
AMRB | -0.925 |
NETE | -0.87 |
MMAC | -0.862 |
LWAC | -0.846 |
CINC | -0.838 |
DWSH | -0.838 |
SRAC | -0.819 |
UMPQ | -0.806 |
NVEI | -0.801 |
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Decibel Therapeutics, Korrelation - Währung/Rohstoff
Decibel Therapeutics, Finanzdaten
Annual | 2022 |
Umsatz: | $0 |
Bruttogewinn: | $0 (0.00 %) |
EPS: | $-2.52 |
FY | 2022 |
Umsatz: | $0 |
Bruttogewinn: | $0 (0.00 %) |
EPS: | $-2.52 |
FY | 2021 |
Umsatz: | $0.00 |
Bruttogewinn: | $0.00 (0.00 %) |
EPS: | $-2.08 |
FY | 2020 |
Umsatz: | $0.00 |
Bruttogewinn: | $0.00 (0.00 %) |
EPS: | $-1.701 |
Financial Reports:
No articles found.
Decibel Therapeutics,
Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. The company's lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. It is also developing DB-ATO and AAV.201, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the vestibule; DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial; AAV.103 to restore hearing in individuals with a gap junction beta-2 (GJB2) deficiency; AAV.104 to restore hearing in individuals with stereocilin (STRC) deficiency; and cochlear hair cell regeneration program, an AAV-based gene therapy that utilizes cell-selective expression of reprogramming factors to convert supporting cells into outer hair cells. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.